Follow DRNO on...
Pharma information giant IQVIA has reported revenue up 7.2% at constant currency for the quarter ended March 31st, to $2.684 billion, and adjusted EBITDA of $587m, up from $547m a year previously. More
Pharma research giant IMS Health has reported second quarter revenue up 5.2% on a like-for-like basis, allowing for currency changes and the acquisition of assets of Cegedim. Reported revenue was up 12.0% to $742m, equivalent to a 24.6% rise at constant currency. More
Pharma data giant IMS Health has announced results for the quarter ended March 31st, with revenue up 7.0% at constant currency, to $632m and profit also jumping - adjusted EBITDA was $216n, up 9.8% at constant currency. More
Pharma research and data giant IMS Health has announced results for the quarter and year ended December 31st 2014, including revenue up 6.2% to $678m in Q4 and 5.9% to $2,641m for the full year on a constant currency basis; and adjusted EBITDA up 8.5% and 9.5% respectively. More
Pharma research and data giant IMS Health has announced results for the quarter ended September 30th, with revenue up 5.4% (constant currencies) to $656m, driven by a strong performance in technology services (up 10.8%). Profits were also healthy - adjusted EBITDA increased 10.5% to $221m. More
Pharma research giant IMS Health has reported a 6.1% increase in second quarter revenue to $662m. However, due to a number of one-off charges and expenses the firm suffered a Q2 net loss of $200m, compared with net income of $8m in the prior year period. More
The world's 25 largest research firms had revenues of $18.8 billion in 2010, up 4.9% on the previous 'dismal' year - a 'very healthy turnaround' according to industry authority Jack Honomichl. However, 'real' revenues were not quite back to their 2008 levels, and some companies continued to shrink. More
US research giant IMS Health has reported a 3% increase in fourth quarter revenues to $599.2m. The firm has also received shareholder approval for its sale to TPG Capital and the CPP Investment Board. More
Pharma market research giant IMS Health has reported a 6% drop in third-quarter revenue to $540.8m, compared with $573.7m a year earlier. The news follows reports earlier in the week that the Board of Directors is considering selling the company. More
Pharma market research giant IMS Health has reported a 19% drop in Q2 profit to $62.9m from $77.7m a year earlier. Accordingly, the firm is planning to shed a total of 850 staff, or 11% of its global workforce. More
US pharma research giant IMS Health has seen total first quarter revenue fall 8% to $526.9m from $574.2m as the strong dollar impacts on overseas sales. Nevertheless, the quarter saw a sharp rise in net income. More
Pharma research leader IMS Health has announced full-year 2008 revenue up 3% at constant currencies to $2,329.5m. Income grew slightly (2%) and EPS respectably (11%) in real terms. Chairman and CEO David R. Carlucci said the firm was 'positioned to perform well in a slower growth environment'. More
Pharmaceutical research giant IMS Health has reported third-quarter revenue of $574m, up 6%, or a modest 3% year-on-year on a constant dollar basis. However, net income and EPS grew 33% and 41% respectively in the quarter. More
IMS Health has announced second-quarter revenue up 12% (4% at constant currencies) to $600.7m. Operating income rose 11% (1% at constant currencies) to $131.4m. Net income on a GAAP basis was $77.7m, compared with $73.4m in the year-earlier quarter, an increase of 6%. More
Register (free) for Daily Research News
REGISTER FOR NEWS EMAILS
To receive (free) news headlines by email, please register online
